摘要
目的：对比研究氯沙坦、坎地沙坦酯与缬沙坦对早期糖尿病肾病的保护作用。方法：统计分析2011年8月-2013年8月我院收治的97例糖尿病肾病患者的临床资料。结果：组内比较,治疗后氯沙坦组患者的FBG、Hb A1c水平均明显比治疗前低（P〈0.05）,三组患者的PBG水平均明显比治疗前低（P〈0.05）;治疗后氯沙坦组和缬沙坦组患者的TC、TG、LDL-C、UAER水平明显比治疗前低（P〈0.05）。组间比较,氯沙坦组患者的血清TC、TG、LDL-C水平均明显比缬沙坦组低（P〈0.05）;氯沙坦组患者治疗后UAER水平明显比缬沙坦组和坎地沙坦酯组低（P〈0.05）;氯沙坦组患者的不良反应发生率3.0%（1/33）明显比缬沙坦组和坎地沙坦酯组11.8%（4/34）、13.3%（4/30）低（P〈0.05）。结论：氯沙坦比坎地沙坦酯与缬沙坦能够有效保护早期糖尿病肾病。
Objective： To compare and study the protective effects of losartan, valsartan and candesartan cilexctil in tile treatment of early diabetic nephropathy. Methods：The clinical data of 97 cases of patients with diabetic nephropathy ill our hospital from August 2011 to August 2013 were statistically analyzed. Results：Comparison in the groups, The FBG, HbAlc levels after treatment of losartan group were significantly Iower（P〈0.05）, PBG levels of three gronps were significantly lower（P〈0.05）; TC, TG, LDL-C. UAER levels of Iosartan group and valsartan group were significantly lower than before treatment（P〈0.05）. Comparison between the two groups, the serum TC, TG, LDL-C levels of losartan group were significantly lower than valsartan group （P-〈0.05）; the UAER level after treatmcnt of losartan group was significantly lower than valsartan group and Hum cilexetil group（P〈0.05）; the incidence of adverse reactions of losartan group 3.0% （1/33） was significantly lower than valsartan group and candesartan cilexetil group 11.8% （4/34）, 13.3% （4/30） （P 〈0.05）. Conelusion：Losartan can more effectively protect early diabetic nephropathy than candcsartan cilexetil and valsartan.
出处
《中国医药导刊》
2015年第10期1039-1041,共3页
Chinese Journal of Medicinal Guide
关键词
氯沙坦
坎地沙坦酯
缬沙坦
早期糖尿病肾病
保护作用
对比
Losartan
Candesartan cilexetil
Valsartan
Early diabetic nephropathy＇Protection：Contrast
